. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: Clin Pharmacol Ther. 2015 Mar 15;97(4):419–427. doi: 10.1002/cpt.66

Table 4.

Clinical predictors of morphine glucuronide C_max and AUC_0-last.

	Morphine Glucuronide^a
	C_max		AUC_0-last
Parameter	β	P-value	β	P-value
NASH Severity	18.51 (4.72)	0.001	4.11 (1.02)	0.001
Waist Circumference	1.96 (0.87)	0.036	0.40 (0.19)	0.051
Waist-to-Hip Ratio	157 (110)	0.170	48.86 (22.62)	0.044
ALP	3.14 (1.07)	0.008	0.59 (0.25)	0.027
Fasting Glucose	2.27 (0.75)	0.007	0.45 (0.17)	0.017
Triglycerides	0.42 (0.17)	0.019	0.09 (0.04)	0.024
HDL	−1.75 (0.62)	0.011	−0.20 (0.16)	0.216
Insulin	2.05 (0.78)	0.017	0.38 (0.18)	0.049
HOMA-IR	6.20 (2.35)	0.016	1.15 (0.54)	0.046

Data are presented as the regression parameter estimate (β) (standard error [SE] of the parameter estimate).

Sum of molar concentrations of morphine-3- and morphine-6-glucuronide

^b Only NASH Severity remained statistically significant when all significant predictors were included in a multivariable regression model subject to backward elimination

ALP; alkaline phosphatase

NAS+Fibrosis; sum of non-alcoholic fatty liver disease activity and fibrosis scores

HOMA-IR; homeostasis model for assessing insulin resistance